122 related articles for article (PubMed ID: 37939778)
1. An innovative nanoformulation utilizing tumor microenvironment-responsive PEG-polyglutamic coating and dynamic charge adjustment for specific targeting of ER stress inducer, microRNA, and immunoadjuvant in pancreatic cancer: In vitro investigations.
Li CY; Chou TF; Lo YL
Int J Biol Macromol; 2024 Jan; 254(Pt 2):127905. PubMed ID: 37939778
[TBL] [Abstract][Full Text] [Related]
2. Exploring in vivo combinatorial chemo-immunotherapy: Addressing p97 suppression and immune reinvigoration in pancreatic cancer with tumor microenvironment-responsive nanoformulation.
Lo YL; Li CY; Chou TF; Yang CP; Wu LL; Chen CJ; Chang YH
Biomed Pharmacother; 2024 Jun; 175():116660. PubMed ID: 38701563
[TBL] [Abstract][Full Text] [Related]
3. Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer.
Yao Z; Qi C; Zhang F; Yao H; Wang C; Cao X; Zhao C; Wang Z; Qi M; Yao C; Wang X; Xia H
Acta Biomater; 2024 Jan; 173():365-377. PubMed ID: 37890815
[TBL] [Abstract][Full Text] [Related]
4. Endoplasmic reticulum stress-induced exosomal miR-27a-3p promotes immune escape in breast cancer via regulating PD-L1 expression in macrophages.
Yao X; Tu Y; Xu Y; Guo Y; Yao F; Zhang X
J Cell Mol Med; 2020 Sep; 24(17):9560-9573. PubMed ID: 32672418
[TBL] [Abstract][Full Text] [Related]
5. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.
Daunke T; Beckinger S; Rahn S; Krüger S; Heckl S; Schäfer H; Wesch D; Pilarsky C; Eckstein M; Hartmann A; Röcken C; Wandmacher AM; Sebens S
Front Immunol; 2023; 14():1157397. PubMed ID: 37449210
[TBL] [Abstract][Full Text] [Related]
6. A cyclodextrin-based nanoformulation achieves co-delivery of ginsenoside Rg3 and quercetin for chemo-immunotherapy in colorectal cancer.
Sun D; Zou Y; Song L; Han S; Yang H; Chu D; Dai Y; Ma J; O'Driscoll CM; Yu Z; Guo J
Acta Pharm Sin B; 2022 Jan; 12(1):378-393. PubMed ID: 35127393
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
Kajiwara Y; Tazawa H; Yamada M; Kanaya N; Fushimi T; Kikuchi S; Kuroda S; Ohara T; Noma K; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
Cancer Immunol Immunother; 2023 May; 72(5):1285-1300. PubMed ID: 36436021
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer.
Thakur PC; Miller-Ocuin JL; Nguyen K; Matsuda R; Singhi AD; Zeh HJ; Bahary N
J Transl Med; 2018 Jul; 16(1):190. PubMed ID: 29986726
[TBL] [Abstract][Full Text] [Related]
9. Penfluridol induces endoplasmic reticulum stress leading to autophagy in pancreatic cancer.
Ranjan A; German N; Mikelis C; Srivenugopal K; Srivastava SK
Tumour Biol; 2017 Jun; 39(6):1010428317705517. PubMed ID: 28618969
[TBL] [Abstract][Full Text] [Related]
10. Calreticulin promotes EMT in pancreatic cancer via mediating Ca
Sheng W; Wang G; Tang J; Shi X; Cao R; Sun J; Lin YH; Jia C; Chen C; Zhou J; Dong M
J Exp Clin Cancer Res; 2020 Oct; 39(1):209. PubMed ID: 33028359
[TBL] [Abstract][Full Text] [Related]
11. PEG-coated nanoparticles detachable in acidic microenvironments for the tumor-directed delivery of chemo- and gene therapies for head and neck cancer.
Lo YL; Chang CH; Wang CS; Yang MH; Lin AM; Hong CJ; Tseng WH
Theranostics; 2020; 10(15):6695-6714. PubMed ID: 32550898
[No Abstract] [Full Text] [Related]
12. New Hope for Pancreatic Ductal Adenocarcinoma Treatment Targeting Endoplasmic Reticulum Stress Response: A Systematic Review.
Garcia-Carbonero N; Li W; Cabeza-Morales M; Martinez-Useros J; Garcia-Foncillas J
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30134550
[TBL] [Abstract][Full Text] [Related]
13. miR-194-5p down-regulates tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer.
Wang C; Li X; Zhang L; Chen Y; Dong R; Zhang J; Zhao J; Guo X; Yang G; Li Y; Gu C; Xi Q; Zhang R
Int Immunopharmacol; 2021 Aug; 97():107822. PubMed ID: 34098485
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of the induction of endoplasmic reticulum stress by the anti-cancer agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT): Activation of PERK/eIF2α, IRE1α, ATF6 and calmodulin kinase.
Merlot AM; Shafie NH; Yu Y; Richardson V; Jansson PJ; Sahni S; Lane DJR; Kovacevic Z; Kalinowski DS; Richardson DR
Biochem Pharmacol; 2016 Jun; 109():27-47. PubMed ID: 27059255
[TBL] [Abstract][Full Text] [Related]
16. Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells.
Nishimura N; Radwan MO; Amano M; Endo S; Fujii E; Hayashi H; Ueno S; Ueno N; Tatetsu H; Hata H; Okamoto Y; Otsuka M; Mitsuya H; Matsuoka M; Okuno Y
Cancer Sci; 2019 Oct; 110(10):3275-3287. PubMed ID: 31368616
[TBL] [Abstract][Full Text] [Related]
17. Reprogramming the T cell response to cancer by simultaneous, nanoparticle-mediated PD-L1 inhibition and immunogenic cell death.
Phung CD; Nguyen HT; Choi JY; Pham TT; Acharya S; Timilshina M; Chang JH; Kim JH; Jeong JH; Ku SK; Choi HG; Yong CS; Kim JO
J Control Release; 2019 Dec; 315():126-138. PubMed ID: 31672625
[TBL] [Abstract][Full Text] [Related]
18. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
19. Tumor pH-functionalized and charge-tunable nanoparticles for the nucleus/cytoplasm-directed delivery of oxaliplatin and miRNA in the treatment of head and neck cancer.
Lo YL; Lin HC; Tseng WH
Acta Biomater; 2022 Nov; 153():465-480. PubMed ID: 36115656
[TBL] [Abstract][Full Text] [Related]
20. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.
Koikawa K; Kibe S; Suizu F; Sekino N; Kim N; Manz TD; Pinch BJ; Akshinthala D; Verma A; Gaglia G; Nezu Y; Ke S; Qiu C; Ohuchida K; Oda Y; Lee TH; Wegiel B; Clohessy JG; London N; Santagata S; Wulf GM; Hidalgo M; Muthuswamy SK; Nakamura M; Gray NS; Zhou XZ; Lu KP
Cell; 2021 Sep; 184(18):4753-4771.e27. PubMed ID: 34388391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]